To use this site, please disable the ad blocking feature and reload the page.
This website uses cookies to collect information about your visit for purposes such as showing you personalized ads and content, and analyzing our website traffic. By clicking “Accept all,” you will allow the use of these cookies.
Users accessing this site from EEA countries and UK are unable to view this site without your consent. We apologize for any inconvenience caused.
Yomiuri Shimbun file photo The Health, Labor and Welfare Ministry
The Yomiuri Shimbun
15:35 JST, September 26, 2023
The Health, Labor and Welfare Ministry on Monday formally approved the respiratory syncytial virus vaccine developed by British pharmaceutical company GSK PLC. It is the first time Japan has approved an RSV vaccine for use in adults aged 60 or older.
The RS virus causes symptoms like those of the common cold but can lead to severe pneumonia for those with weakened immune systems, including infants and elderly people.
According to GSK, the vaccine lowered the risk of pneumonia and bronchitis by about 80% in adults aged 60 or older in its vaccine efficacy trials.
U.S. pharmaceutical company Pfizer Inc. has also applied for approval of its RSV vaccine.
